Recursion Pharmaceuticals (RXRX)

Recursion operates automated laboratories and generates high-dimensional biological data from cellular experiments, including image-based phenomics. These datasets are combined with chemical, genetic, and clinical information to support target identification, compound screening, and drug candidate selection. The company refers to this integrated system as the Recursion OS, a platform intended to industrialize parts of the discovery process and improve the probability of finding meaningful drug-biology matches.

The company’s pipeline includes internally developed and partnered programs across areas such as oncology, rare disease, inflammation, and neuroscience. As a clinical-stage business, Recursion’s value is tied less to current product sales and more to the progress of its drug candidates, the strength of its discovery platform, and its ability to form research collaborations with larger pharmaceutical companies.

Headquartered in the United States, Recursion also has operations and research capabilities in other markets, including the United Kingdom. Its business model blends biotechnology development with software, data science, chemistry, engineering, and automation, making it part of a growing group of companies seeking to use artificial intelligence and industrial-scale experimentation to reshape how new medicines are discovered.